Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +65

Abbott Laboratories $ABT Shares Sold by Aaron Wealth Advisors LLC

AI-generated analysis

📉 Aaron Wealth Advisors LLC reduced its Abbott Laboratories position by 53.3% in Q1, selling 15,701 shares while retaining 13,746 shares valued at $1.41 million.

📈 American National Bank of Texas increased its stake by 2.4% to own 3,408 shares worth $427,000 during the fourth quarter.

📈 Nia Impact Advisors LLC grew its holdings by 2.2% in Q2, now owning 3,706 shares valued at $504,000.

📈 Park Place Capital Corp increased its position by 11.0% in Q4 to hold 815 shares worth $102,000.

📈 Lantern Wealth Advisors LLC raised its stake by 1.7% in Q3 to own 5,028 shares valued at $674,000.

📈 Clayton Financial Group LLC lifted its holdings by 1.4% in Q4 to own 6,217 shares worth $779,000.

💰 Director Daniel J. Starks purchased 10,000 shares for $926,500 on April 27th, increasing his total ownership to 6,751,103 shares valued at over $625 million.

💰 CFO Philip P. Boudreau bought 2,200 shares for $201,300 on April 23rd at an average price of $91.50 per share.

📊 Abbott Laboratories reported Q1 revenue of $11.16 billion, beating the consensus estimate of $10.99 billion by $174 million.

💹 The company posted EPS of $1.15, surpassing analyst expectations of $1.14 and showing a 7.8% year-over-year revenue increase.

📅 Abbott Laboratories provided FY 2026 guidance of $5.38-$5.58 EPS and Q2 2026 guidance of $1.25-$1.31 EPS.

💸 The company declared a quarterly dividend of $0.63 per share, payable on August 17th with an ex-dividend date of July 15th.

🏦 Abbott Laboratories maintains a market cap of $163.77 billion and a P/E ratio of 26.34 as of the latest trading session.

📉 The stock trades at a fifty-day moving average of $89.08 and a 200-day moving average of $105.38, with a current price of $94.02.

🛡️ The company holds a healthy balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.

Bullish Signals
  • Abbott Laboratories beat quarterly revenue estimates by $174 million, reporting $11.16 billion versus the consensus of $10.99 billion.
  • The company exceeded earnings expectations with EPS of $1.15 compared to the analyst consensus of $1.14.
  • Revenue grew 7.8% year-over-year, demonstrating solid top-line growth in the healthcare sector.
  • Director Daniel J. Starks purchased over $926,000 worth of shares, signaling strong insider confidence in the company's future prospects.
  • CFO Philip P. Boudreau added to his personal holdings by purchasing 2,200 shares, further reinforcing insider support.
  • The company provided clear forward guidance for FY 2026 EPS between $5.38 and $5.58, aligning with analyst predictions of $5.48.
  • Abbott Laboratories declared a quarterly dividend of $0.63 per share, offering investors a yield of 2.7% and demonstrating commitment to shareholder returns.
  • The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.56 and a strong current ratio of 1.39.
Risk Factors
  • Aaron Wealth Advisors LLC significantly reduced its position by 53.3% in the first quarter, selling over 15,000 shares.
  • The stock price is currently trading below both its fifty-day and 200-day moving averages at $94.02 versus $89.08 and $105.38 respectively.
Full Analysis
Abbott Laboratories (NYSE:ABT) saw institutional ownership shifts in the first quarter, led by Aaron Wealth Advisors LLC reducing its position by 53.3% to hold 13,746 shares valued at $1.41 million. Conversely, several smaller institutional investors increased their stakes, including American National Bank of Texas and Nia Impact Advisors LLC, while hedge funds collectively own 75.18% of the company's stock. Company insiders also made notable purchases, with Director Daniel J. Starks buying 10,000 shares for $926,500 in April, bringing his total holding to over 6.7 million shares worth approximately $625 million. CFO Philip P. Boudreau purchased an additional 2,200 shares at an average price of $91.50, signaling continued insider confidence in the stock despite recent institutional selling. Financially, Abbott reported strong quarterly results with revenue of $11.16 billion, beating estimates by $174 million and posting EPS of $1.15 versus a consensus of $1.14. The company provided FY 2026 guidance ranging from $5.38 to $5.58 per share and declared a quarterly dividend of $0.63 per share, payable on August 17th with an ex-dividend date of July 15th. The healthcare giant operates through diagnostics, medical devices, nutritionals, and pharmaceuticals, maintaining a market cap of $163.77 billion and a P/E ratio of 26.34. With a debt-to-equity ratio of 0.56 and a current ratio of 1.39, the company presents a solid balance sheet as it continues to expand its portfolio of medical products and services globally.